Celltrion’s ambitious intestinal disease management app, named “Manager Care,” has been confirmed to suffer from sluggish download numbers four months after its launch, according to market watchers.
On Tuesday, Celltrion said it would launch the intestinal disease management service app Manager Care to promote the convenience of patients with intestinal diseases.
Manager Care is a mobile app launched to effectively manage diseases in patients with irritable bowel syndrome (IBS). It is equipped with various functions, such as patient status records, including symptoms of disease, dietary and medication records, a database-based disease trend report, and consultation with experts.
However, according to confirmation by this paper, Oct. 4 was only the update date, and the actual release date of Manager Care was May 2 based on the Google Play Store, indicating four months have passed since its real release date.
The number of application downloads has also been low. Currently, Manager Care is released in iOS and Android versions, respectively. However, the number of downloads of the Google Play Store that can download the Android version is more than 500 times, falling short of even 1,000 times.
Celltrion said it had formed a team within its research and development unit exclusively responsible for examining various patient support programs and potential business models using digital equipment since 2019. Hence, the download number is relatively poor.
Later in the day, Celltrion said it would actively manage IBS and IBD (inflammatory bowel disease) patients by expanding independently developed apps, including Manager Care. The company added that it would also consider developing them as various business models through upgrading services and accumulating data.
The company also said it would seek synergy with its biosimilar products in the future. It will make particular efforts to find services that can create synergy with autoimmune disease treatments, such as Remicade biosimilar Remsima (infliximab) product line (IV·SC formulation) and Humira biosimilar Yuflyma (adalimumab).